BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2018-04-23 13:44 |
BerGenBio ASA (BGBIO): Notice of annual general meeting
|
English | 86.9 KB | ||
| 2018-04-23 13:44 |
BerGenBio ASA (BGBIO): Notice of annual general meeting
|
English | 1.5 KB | ||
| 2018-04-23 13:35 |
BerGenBio ASA (OSE:BGBIO): Annual report 2017
|
English | 4.0 MB | ||
| 2018-04-23 13:35 |
BerGenBio ASA (OSE:BGBIO): Annual report 2017
|
English | 1.5 KB | ||
| 2018-04-19 07:39 |
BerGenBio ASA: Share capital increase
|
English | 1.8 KB | ||
| 2018-04-18 06:00 |
BerGenBio: Promising data highlighting selective AXL inhibitor bemcentinib's po…
|
English | 5.8 KB | ||
| 2018-04-18 06:00 |
BerGenBio: Lovende data som viser selektiv AXL inhibitor bemcentinibs potensial…
|
Norwegian | 6.0 KB | ||
| 2018-04-13 11:48 |
BerGenBio ASA: Share capital increase
|
English | 1.9 KB | ||
| 2018-04-13 06:00 |
Promising pre-clinical data supporting BerGenBio's pipeline to be published and…
|
English | 60.8 KB | ||
| 2018-04-13 06:00 |
Promising pre-clinical data supporting BerGenBio's pipeline to be published and…
|
English | 10.8 KB | ||
| 2018-04-13 05:15 |
BerGenBio ASA announces successful NOK 187.5 million (USD 24 million) private p…
|
Norwegian | 50.3 KB | ||
| 2018-04-13 05:15 |
BerGenBio ASA announces successful NOK 187.5 million (USD 24 million) private p…
|
English | 11.7 KB | ||
| 2018-04-10 06:00 |
BerGenBio completes recruitment into first stage of Phase II NSCLC trial with s…
|
English | 54.0 KB | ||
| 2018-04-10 06:00 |
BerGenBio completes recruitment into first stage of Phase II NSCLC trial with s…
|
English | 7.2 KB | ||
| 2018-04-05 15:54 |
BerGenBio ASA: Board approval of 2017 annual financial statement
|
English | 1.7 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
